Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Bethlehem, PA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Charleston, SC
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Greenville, SC
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Austin, TX
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Houston, TX
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
San Antonio, TX
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Sugar Land, TX
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Sugar Land, TX
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Arlington, VA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Arlington, VA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Seattle, WA
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated:  3/10/2016
GSK Investigational Site
mi
from
Onalaska, WI
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Status: Enrolling
Updated: 3/10/2016
GSK Investigational Site
mi
from
Onalaska, WI
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Division of Clinical Immunology and Rheumatology - UAB
mi
from
Birmingham, AL
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Division of Clinical Immunology and Rheumatology - UAB
mi
from
Birmingham, AL
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Stanford University
mi
from
Palo Alto, CA
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Clinical Research Facility
mi
from
San Diego, CA
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Inland Rheumatology Clinical Trials, Inc.
mi
from
Upland, CA
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Inland Rheumatology Clinical Trials, Inc.
mi
from
Upland, CA
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Clinical Research Facility
mi
from
Boise, ID
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
US Local Medical Information
mi
from
Rockland, MA
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
US Local Medical Information
mi
from
Rockland, MA
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Wayne State University
mi
from
Detroit, MI
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Justus J. Fiechtner, MD, MPH
mi
from
Lansing, MI
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Justus J. Fiechtner, MD, MPH
mi
from
Lansing, MI
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
SUNY Health Science Center at Brooklyn
mi
from
Brooklyn, NY
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
SUNY Health Science Center at Brooklyn
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Hospital for Special Surgey
mi
from
New York, NY
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Hospital for Special Surgey
mi
from
New York, NY
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Clinical Research Facility
mi
from
New York, NY
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
University of Cincinnati Medical Center, Division of Immunology
mi
from
Cincinnati, OH
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
University of Cincinnati Medical Center, Division of Immunology
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Clinical Research Facility
mi
from
Temple, TX
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  3/11/2016
mi
from
Buenos Aires,
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 3/11/2016
mi
from
Buenos Aires,
Click here to add this to my saved trials
Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
Dipyridamole Assessment for Flare Reduction in SLE
Status: Enrolling
Updated:  3/28/2016
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
Dipyridamole Assessment for Flare Reduction in SLE
Status: Enrolling
Updated: 3/28/2016
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
La Rabida Children's Hospital - The University of Chicago
mi
from
Chicago, IL
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
La Rabida Children's Hospital - The University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
New England Medical Center -Tufts
mi
from
Boston, MA
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
New England Medical Center -Tufts
mi
from
Boston, MA
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
St. Barnabas Medical Center
mi
from
Livingston, NJ
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
St. Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
Hospital for Special Surgery
mi
from
New York, NY
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
Cleveland Clinic
mi
from
Cleveland, OH
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
University Hospital Case Medical Center
mi
from
Cleveland, OH
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
University Hospital Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated:  4/8/2016
Legacy Health System
mi
from
Portland, OR
Health-related Quality of Life Measure in Pediatric Lupus
Health-related Quality of Life Measure in Pediatric Lupus
Status: Enrolling
Updated: 4/8/2016
Legacy Health System
mi
from
Portland, OR
Click here to add this to my saved trials
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
San Leandro, CA
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
San Leandro, CA
Click here to add this to my saved trials
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Danbury, CT
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Manhasset, NY
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated:  4/20/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated: 4/20/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated:  4/20/2016
Research Site
mi
from
St Leonards,
Safety Study of AMG 557 in Subjects With Lupus Arthritis
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
Status: Enrolling
Updated: 4/20/2016
Research Site
mi
from
St Leonards,
Click here to add this to my saved trials
Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention
Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?
Status: Enrolling
Updated:  5/17/2016
University of Michigan
mi
from
Ann Arbor, MI
Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention
Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?
Status: Enrolling
Updated: 5/17/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Status: Enrolling
Updated:  12/15/2016
Clinical Research Facility
mi
from
La Jolla, CA
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Status: Enrolling
Updated: 12/15/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Status: Enrolling
Updated:  12/15/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Status: Enrolling
Updated: 12/15/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials